Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares traded up 7.9% during mid-day trading on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. 171,529 shares traded hands during trading, a decline of 41% from the average session volume of 292,811 shares. The stock had previously closed at $19.65.

A number of other analysts have also recently issued reports on the company. Jones Trading reduced their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a research report on Friday, May 16th. Robert W. Baird lifted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, June 16th. Finally, The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research report on Monday, June 16th. They set a “buy” rating and a $37.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $41.20.

Insider Buying and Selling

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the completion of the sale, the chief executive officer owned 952,892 shares of the company’s stock, valued at $21,135,144.56. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $20.91, for a total value of $67,957.50. Following the completion of the sale, the chief financial officer directly owned 23,000 shares of the company’s stock, valued at $480,930. This represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 100,111 shares of company stock worth $1,939,549 over the last ninety days. 25.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its position in shares of Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock worth $146,157,000 after buying an additional 199,692 shares during the last quarter. Polar Capital Holdings Plc increased its stake in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the period. Vanguard Group Inc. increased its stake in shares of Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock worth $44,452,000 after purchasing an additional 55,283 shares during the period. Janus Henderson Group PLC increased its stake in shares of Enliven Therapeutics by 27.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock worth $30,001,000 after purchasing an additional 290,153 shares during the period. Finally, Pictet Asset Management Holding SA increased its stake in shares of Enliven Therapeutics by 16.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

The business has a 50 day moving average price of $19.49 and a 200 day moving average price of $20.40. The firm has a market capitalization of $1.01 billion, a P/E ratio of -10.75 and a beta of 0.83.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.